Kidney Week

• What's New in 2017
• General Information
  • Meeting Overview
  • Chairs' Message
  • Schedule-at-a-Glance
  • Important Dates
  • Accreditation and CME
  • Ancillary Events
  • Career Fair
  • Travel Support Information
  • Travel Information
  • New Orleans Information
  • Social Media Policy
  • Certificates of Attendance
  • Kidney Week Mobile App
  • #KidneyWk
• Registration Information
  • Registration Overview
  • Registration FAQ
  • Register Online
• Housing Information
  • Housing Overview
  • Housing FAQ
  • Hotel List and Map
  • Reserve Housing Online
• First Time Attendees
• International Attendees
  • Group Assistance
  • Visa Information
  • Download Invitation Letter
• Abstract Information
  • Call for Abstracts
  • Late-Breaking Clinical Trials
  • Category Descriptions
  • Abstract Experts
  • Submission Site
  • Author Disclosure
  • ASN Embargo Policy
  • Poster Information
  • Abstract Archives
  • Search Abstracts
  • Abstract FAQs
• Program Information
  • Preliminary Program
  • Onsite Program
  • Early Programs (Tues-Wed)
  • Annual Meeting (Thurs-Sun)
  • Learning Pathways
  • Trainees Track
  • Session List (PDF)
  • Educational Symposia
  • Kidney Week Faculty
  • Kidney Week Disclosures
  • Fellows Activities
  • My Favorites
  • Webcasts
• Scientific Exposition
  • Exhibits
  • Exhibitor Prospectus
  • Exhibitor Service Manual
  • Exhibitor Spotlights
  • Exhibit Contacts
• Support Opportunities
• Faculty Resources
  • COI & Disclosure
  • ASN Expert Website
  • Presentation Information
  • Speaker Ready Room
• Press Information
  • Press Policies
  • Press Registration
  • ASN Embargo Policy
• Past Kidney Weeks
• Future Meeting Dates

Abstract: TH-PO552

Effect of N-Acetyl Cysteine in Patients with CKD: The Longer, the Better? A Nationwide Population-Based Retrospective Cohort Study

Session Information

• CKD: Health Services, Disparities, Prevention
  November 02, 2017 | Location: Hall H, Morial Convention Center
  Abstract Time: 10:00 AM - 10:00 AM

Category: Chronic Kidney Disease (Non-Dialysis)

• 307 CKD: Health Services, Disparities, Prevention

Authors

• Liao, Chen-Yi, Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan

Chen-Yi Liao,



• Wu, Chia-chao, Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan

Chia-chao Wu,

Background

This study aimed to evaluate the potential benefits of N-acetylcysteine (NAC) on the risk for chronic kidney disease (CKD) progression to dialysis-requiring end-stage renal disease (ESRD)

Methods

In a population-based cohort study of 145,062 individuals, a total of 123,608 CKD patients who were followed up for 10 years were compared with patients who were prescribed NAC after been diagnosed as CKD (ICD-9-CM). Using propensity score matching, we analyzed the predictors of CKD progression to ESRDd by Cox proportional hazards regression with adjustment for sex, age, and comorbidities and evaluated the effect of NAC using cumulative defined daily dose (cDDD).

Results

NAC use was associated with reduced risk for progression to ESRDd (HR 0.819, 95% CI 0.781-0.965, p = 0.017). Risk reduction was accentuated by an increase in cDDD in patients on NAC compared with non-NAC users (HR was 0.8350, 0.811, and 0.799 for cDDDs 91-180, 180-360, and ≥360, respectively; P for trend =0.018). Risk reduction was apparent in women (P = 0.001); younger age at 18-29 years (P = 0.021) and 30–39 years (P = 0.033); the presence of hypertension (P = 0.003); the absence of diabetes mellitus (P = 0.042); and the absence of congestive heart failure (P = 0.036).

Conclusion

NAC administration was associated with a lower risk of subsequent ESRD. Further studies are warranted to confirm these findings.